NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections ...

Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced it advanced to a new expansion arm of its Phase 1b/2 clinical trial of ...

About PD-1 Inhibitors PD-1 inhibitors work by blocking the PD-1 (programmed death-1) receptor on T cells, preventing cancer cells from evading the immune system and restoring the body’s ability to ...

Indaptus Therapeutics announced significant progress in its Phase 1 trial of Decoy20, with over 20 patients enrolled in the weekly dosing cohort. Initial clinical data shows promising ...

(RTTNews) - Indaptus Therapeutics, Inc.(INDP), Monday announced the initiation of a new expansion arm in its Phase 1b/2 clinical trial to evaluate the combination of Decoy20 with BeiGene's PD-1 ...

The latest results from the weekly dosing cohort show that Decoy20 is generally well-tolerated and has led to immune cell trafficking, a key process in effective anticancer immune response.

The INDP-D101 trial will now admit Canadian patients under the existing protocol, which includes weekly dosing of Decoy20. Furthermore, Indaptus intends to propose an amendment to Health Canada to ...

Indaptus began a new expansion phase of its Decoy20 trial, combining it with BeiGene’s tislelizumab to assess safety and anti-tumor activity The company expects its cash reserves to fund ...

Initial data indicate that Decoy20 at the 30 million cell dose was generally well-tolerated, with a favorable safety profile and promising early signs of clinical benefit, including some patients ...

This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.